吗替麦考酚酯治疗免疫相关性皮肤病专家建议  

Mycophenolate mofetil in the treatment of immune-related skin diseases:an expert proposal

作　　者：无 邓丹琪 左亚刚[3] 郭竹秀[4] 廖理超 刘毅[6] 吕新翔[7] 王鹏[8] 赵梓纲[9] 甄莉 

机构地区：[1]中国医师协会皮肤科医师分会自身免疫性疾病专业委员会 [2]昆明医科大学第二附属医院 [3]中国医学科学院北京协和医院 [4]南昌大学第一附属医院 [5]中国科学技术大学附属第一医院安徽省立医院 [6]中国医学科学院皮肤病医院 [7]内蒙古医科大学附属医院 [8]新疆维吾尔自治区人民医院 [9]解放军总医院海南医院 [10]山西医科大学第一医院

出　　处：《中华皮肤科杂志》2020年第11期869-874,共6页Chinese Journal of Dermatology

摘　　要：吗替麦考酚酯可选择性抑制T、B淋巴细胞的增殖和活性,已广泛应用于多种免疫相关性皮肤病的治疗。在检索国内外文献的基础上,中国不同地域多位专家讨论和撰写了本建议。根据英国牛津大学循证医学中心制定的推荐等级标准,吗替麦考酚酯在成人中重度寻常型斑块状银屑病、成人大疱性类天疱疮和寻常型天疱疮的治疗中属于A级推荐;在成人系统性硬化症、成人中重度湿疹和中重度特应性皮炎的治疗中均属于B级推荐;在皮肤型红斑狼疮、皮肌炎、无肌病性皮肌炎、儿童系统性硬化症、儿童大疱性类天疱疮和儿童天疱疮、儿童中重度湿疹和特应性皮炎的治疗中属于C级推荐。Mycophenolate mofetil can selectively inhibit the proliferation and activity of T and B lymphocytes,and has been widely used in the treatment of a variety of immune-related skin diseases.On the basis of Chinese and international literature,a proposal was formed after discussion among multiple experts from different regions in China.According to the criteria for grading the strength of recommendations established by the Oxford Centre for Evidence-based Medicine,the strength of recommendation is grade A for use of mycophenolate mofetil in the treatment of moderate to severe adult plaque psoriasis vulgaris,adult bullous pemphigoid and pemphigus vulgaris,grade B for use of mycophenolate mofetil in the treatment of adult systemic sclerosis,moderate to severe adult eczema and moderate to severe atopic dermatitis,and grade C for use of mycophenolate mofetil in the treatment of cutaneous lupus erythematosus,dermatomyositis,amyopathic dermatomyositis,childhood systemic sclerosis,childhood bullous pemphigoid and childhood pemphigus,moderate to severe childhood eczema and atopic dermatitis.

关 键 词：自身免疫疾病 银屑病 类天疱疮 大疱性 天疱疮 硬皮病 系统性 皮炎 皮肌炎 吗替麦考酚酯 

分 类 号：R751.05[医药卫生—皮肤病学与性病学]